FDA Drug recall D-0454-2023
DIBUCAINE 1% HEMORRHOIDAL OINTMENT, 1 oz. (28 gm), Manufactured for: Akron Pharma Inc
- FDA Drug
- Class III
- terminated
- Published 2023-03-15
On 2023-03-15 the FDA classified a Class III recall of DIBUCAINE 1% HEMORRHOIDAL OINTMENT, 1 oz. (28 gm), Manufactured for: Akron Pharma Inc by Akron Pharma, citing labeling: Incorrect or Missing Lot and/or Exp Date.
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-0454-2023 |
| Classification | Class III |
| Status | terminated |
| Initiated | 2023-02-17 |
| Published | 2023-03-15 |
| Last updated | 2026-09-13 11:52 UTC |
| Company | Akron Pharma |
| Distribution | US |
Product
DIBUCAINE 1% HEMORRHOIDAL OINTMENT, 1 oz. (28 gm), Manufactured for: Akron Pharma Inc. Fairfield NJ 07004, NDC 71399-2829-1
Reason
Labeling: Incorrect or Missing Lot and/or Exp Date
Identifiers
| ndc | 71399-2829-1 |
|---|---|
| ndc | 71399-2829-2 |
| code_info | Lot #: 2206016, Exp. date 05/2024 |
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0454-2023%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.